Overview

Safety and Pharmacokinetics Study in Adults for the Prevention of S. Epidermidis Infection in Low Birth Weight Infants

Status:
Completed
Trial end date:
2001-11-01
Target enrollment:
Participant gender:
Summary
The purpose of this Phase 1 study is to evaluate the safety and pharmacokinetics of BSYX-A110 in a small number of healthy adult volunteers. Following the demonstration of safety in adults, this anti-Staphylococcal monoclonal antibody will then be evaluated in the target population of hospitalized low birth weight neonates.
Phase:
Phase 1
Details
Lead Sponsor:
Biosynexus Incorporated
Treatments:
Antibodies, Monoclonal